Spago Nanomedical AB (publ), a nanomedicine company, engages in the development projects based on a platform of polymeric materials for diagnosis and treatment of life-threatening and debilitating diseases in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment of liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of cancer. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. The company was incorporated in 1999 and is based in Lund, Sweden.…
Bulletin from the Extraordinary General Meeting of Spago Nanomedical AB
Spago Nanomedical (STO: SPAGO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 0.0410 SEK on 20 November 2026, down 66.4% over 52 weeks. Its 52-week range is 0.0310 SEK to 0.1740 SEK: the price is 76.4% below the high and 32.3% above the low.
Its market capitalisation is 32.73M SEK.
Spago Nanomedical reports return on equity of -86.4% and revenue down 75.8% year over year.
It holds more cash than debt, a net cash position of 24.52M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.